Altimmune, Inc.

NASDAQ:ALT

Biotechnology

Healthcare
$1.39 +3.09%

+$0.08 today

Market cap
$270.48M
Beta
0.23
P/E (TTM)
-3.7
EPS (TTM)
-$0.73
52W Low $2.56High $7.73

Volume 4.69M

Average 3.81M

ALT Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Altimmune, Inc.NASDAQ: ALT

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash growth accelerates

Q1 FY2026 net change in cash of $53.84M rose 342.1% year over year, ahead of the +262.3% change in trailing-twelve-month net change in cash.

Context

  • Net change in cash amounted to 16668.3% of revenue in FY2025, down 474281.7 pp from a year earlier.
  • Net change in cash increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +342.1% holds above the trailing-twelve-month pace of +262.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$53.84M+408.1% QoQ
Last fiscal yearDec 2025
$6.83M+107.0% YoY
LTMMar 2026
$48.5M+262.3% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+342.1%——
1 year+107.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
6.83M USD
Year-over-year change
+107.0%
4-year CAGR
-44.9%

Net Change in Cash vs competitors

How ALT compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +262.3% is the 2nd highest of 9, against a peer median of +58.9%.
  • Net change in cash amounts to 134713.9% of revenue for ALT, versus a peer median of 36.5%.
ALT Competitors
Net Change in Cash for ALT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GPCRStructure Therapeutics Inc.LTM Jun 2026$357.83M USD+52.5%——
VIRVir Biotechnology, Inc.LTM Mar 2026$84.95M USD-145.3%—129.7%
ALTAltimmune, Inc.LTM Mar 2026$48.5M USD+262.3%—134713.9%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$25.29M USD+542.2%-17.4%36.5%
IVAInventiva S.A.FY2025€14.17M EUR-79.7%+326.2%316.0%
ABUSArbutus Biopharma CorporationLTM Mar 2026$13.37M USD+121.9%-38.4%7.0%
BMEABiomea Fusion, Inc.LTM Mar 2026$9.2M USD+108.4%-58.2%—
ASMBAssembly Biosciences, Inc.LTM Mar 2026$7.71M USD+65.2%+43.6%10.8%
INDPIndaptus Therapeutics, Inc.LTM Mar 2026$2.39M USD-59.1%——
Peer median (excluding ALT) —+58.9%-17.4%36.5%

Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(97.09M)(84.71M)(88.45M)(95.06M)(88.09M)
Depreciation & Amortization551K493K477K238K112K
Deferred Income Tax0000(681K)
Stock-Based Compensation5.52M8.1M10.64M14.39M16.08M
Change in Working Capital(251K)14.11M(8.27M)4.48M6.75M
Accounts Receivables6.53M3.3M(2.31M)1.74M2.06M
Inventory00000
Accounts Payables1.42M2.77M(2.73M)(1.86M)2.51M
Other Working Capital(8.21M)8.04M(3.23M)4.6M2.19M
Other Non-Cash Items13.03M(578K)9.79M(3.9M)(1.7M)
Operating Cash Flow(78.24M)(62.59M)(75.81M)(79.85M)(67.54M)
Capital Expenditures(12.31M)(126K)(47K)0(11K)
Acquisitions (Net)00000
Purchases of Investments(7.59M)(73.27M)(88.63M)(115.73M)(285.45M)
Sales of Investments107.43M0102.41M87.35M152.99M
Other Investing Activities(195K)0000
Investing Cash Flow87.52M(73.4M)13.73M(28.39M)(132.47M)
Debt Repayment000033.92M
Common Stock Issued65.04M56.35M86.6M9.99M173.73M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities58K434K(496K)50K(709K)
Financing Cash Flow65.1M56.78M86.11M10.04M206.84M
Effect of Forex Changes00000
Net Change in Cash74.38M(79.2M)24.03M(98.19M)6.83M
Free Cash Flow(90.55M)(62.71M)(75.86M)(79.85M)(67.55M)

Altimmune, Inc.

NASDAQ:ALT

Intrinsic Alpha fair value

Locked

Current Price

$1.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.